Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: J Immunol. 2012 Sep 5;189(7):3759–3766. doi: 10.4049/jimmunol.1201529

FIGURE 6. Immunogenicity and anti-tumor activity of Pak6 immunization.

FIGURE 6

(A) Western blots carried out with sera from C57BL/6 and FVB mice immunized twice with PBS plus CFA or with human Pak6 plus CFA (3 mice/group. (B) Proliferation assays carried out with inguinal lymph nodes cells pooled from immunized C57BL/6 and FVB mice incubated with media alone or with the protein as shown. Concentrations are in μg/ml. Proliferation was measured as radioactive counts per min (CPM) of [3H]-thymidine incorporation. Error bars denote ± standard deviations of triplicate wells. (C) Kaplan-Meier survival curve of tumor challenge for C57BL/6 and FVB mice immunized twice with PBS plus CFA or human Pak6 plus CFA (5 mice/group) and challenged 14 days later with Tramp cells. Tumors were measured three times a week and mice were sacrificed when the tumor size reached 2 cm per institutional guidelines. p-values were calculated by using the log rank test (SPSS, IBM). (*) denotes a significant p-value < 0.05.